Document Detail

Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis.
MedLine Citation:
PMID:  22968891     Owner:  NLM     Status:  MEDLINE    
CONTEXT: Considerable controversy exists regarding the association of omega-3 polyunsaturated fatty acids (PUFAs) and major cardiovascular end points.
OBJECTIVE: To assess the role of omega-3 supplementation on major cardiovascular outcomes.
DATA SOURCES: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials through August 2012.
STUDY SELECTION: Randomized clinical trials evaluating the effect of omega-3 on all-cause mortality, cardiac death, sudden death, myocardial infarction, and stroke.
DATA EXTRACTION: Descriptive and quantitative information was extracted; absolute and relative risk (RR) estimates were synthesized under a random-effects model. Heterogeneity was assessed using the Q statistic and I2. Subgroup analyses were performed for the presence of blinding, the prevention settings, and patients with implantable cardioverter-defibrillators, and meta-regression analyses were performed for the omega-3 dose. A statistical significance threshold of .0063 was assumed after adjustment for multiple comparisons.
DATA SYNTHESIS: Of the 3635 citations retrieved, 20 studies of 68,680 patients were included, reporting 7044 deaths, 3993 cardiac deaths, 1150 sudden deaths, 1837 myocardial infarctions, and 1490 strokes. No statistically significant association was observed with all-cause mortality (RR, 0.96; 95% CI, 0.91 to 1.02; risk reduction [RD] -0.004, 95% CI, -0.01 to 0.02), cardiac death (RR, 0.91; 95% CI, 0.85 to 0.98; RD, -0.01; 95% CI, -0.02 to 0.00), sudden death (RR, 0.87; 95% CI, 0.75 to 1.01; RD, -0.003; 95% CI, -0.012 to 0.006), myocardial infarction (RR, 0.89; 95% CI, 0.76 to 1.04; RD, -0.002; 95% CI, -0.007 to 0.002), and stroke (RR, 1.05; 95% CI, 0.93 to 1.18; RD, 0.001; 95% CI, -0.002 to 0.004) when all supplement studies were considered.
CONCLUSION: Overall, omega-3 PUFA supplementation was not associated with a lower risk of all-cause mortality, cardiac death, sudden death, myocardial infarction, or stroke based on relative and absolute measures of association.
Evangelos C Rizos; Evangelia E Ntzani; Eftychia Bika; Michael S Kostapanos; Moses S Elisaf
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review    
Journal Detail:
Title:  JAMA     Volume:  308     ISSN:  1538-3598     ISO Abbreviation:  JAMA     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-09-12     Completed Date:  2012-09-14     Revised Date:  2014-09-17    
Medline Journal Info:
Nlm Unique ID:  7501160     Medline TA:  JAMA     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1024-33     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiovascular Diseases / mortality*,  prevention & control*
Cause of Death
Death, Sudden, Cardiac / epidemiology
Dietary Supplements*
Fatty Acids, Omega-3 / therapeutic use*
Middle Aged
Myocardial Infarction / mortality,  prevention & control
Randomized Controlled Trials as Topic
Stroke / mortality,  prevention & control
Reg. No./Substance:
0/Fatty Acids, Omega-3
Comment In:
Ann Intern Med. 2012 Dec 18;157(12):JC6-5   [PMID:  23247954 ]
JAMA. 2013 Jan 2;309(1):28   [PMID:  23280210 ]
J Fam Pract. 2013 Aug;62(8):422-4   [PMID:  24143335 ]
JAMA. 2013 Jan 2;309(1):29   [PMID:  23280212 ]
JAMA. 2013 Jan 2;309(1):27   [PMID:  23280208 ]
JAMA. 2013 Jan 2;309(1):27-8   [PMID:  23280209 ]
JAMA. 2013 Jan 2;309(1):28-9   [PMID:  23280211 ]
J Miss State Med Assoc. 2013 Jun;54(6):156-7   [PMID:  23991511 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Spending differences associated with the Medicare Physician Group Practice Demonstration.
Next Document:  The surgical safety checklist survey: a national perspective on patient safety.